(HURN) Huron Consulting - Ratings and Ratios
Consulting, Software, Managed Services
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 30.0% |
| Value at Risk 5%th | 42.4% |
| Relative Tail Risk | -14.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.91 |
| Alpha | 22.45 |
| CAGR/Max DD | 1.71 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.470 |
| Beta | 0.732 |
| Beta Downside | 0.597 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.46% |
| Mean DD | 5.83% |
| Median DD | 4.77% |
Description: HURN Huron Consulting January 13, 2026
Huron Consulting Group Inc. (NASDAQ:HURN) delivers management consulting and managed-services solutions across three primary segments-Healthcare, Education, and Commercial-leveraging a portfolio that spans performance-improvement advisory, digital transformation (including ERP, EHR, AI/automation, and CRM), revenue-cycle outsourcing, and specialized software such as the Huron Research suite for research-administration compliance.
In FY 2023 the firm generated roughly $1.2 billion in revenue, with an operating margin near 13%, reflecting strong demand for its healthcare-value-based-care initiatives, while the education segment faces headwinds from declining enrollment and state-budget cuts. A key sector driver is the accelerating adoption of AI-enabled analytics, which is expanding consulting spend across all three verticals, and macro-economic trends such as rising federal healthcare outlays and corporate digital-transformation budgets continue to underpin growth opportunities.
For a deeper, data-driven assessment of HURN’s valuation dynamics, you may find it useful to explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 108.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.41 > 1.0 |
| NWC/Revenue: 8.91% < 20% (prev 11.59%; Δ -2.68% < -1%) |
| CFO/TA 0.13 > 3% & CFO 206.6m > Net Income 108.4m |
| Net Debt (627.0m) to EBITDA (210.1m): 2.98 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.8m) vs 12m ago -3.67% < -2% |
| Gross Margin: 31.58% > 18% (prev 0.32%; Δ 3126 % > 0.5%) |
| Asset Turnover: 113.3% > 50% (prev 108.1%; Δ 5.19% > 0%) |
| Interest Coverage Ratio: 5.83 > 6 (EBITDA TTM 210.1m / Interest Expense TTM 31.4m) |
Altman Z'' 3.35
| A: 0.09 (Total Current Assets 475.0m - Total Current Liabilities 330.1m) / Total Assets 1.54b |
| B: 0.39 (Retained Earnings 606.0m / Total Assets 1.54b) |
| C: 0.13 (EBIT TTM 182.9m / Avg Total Assets 1.44b) |
| D: 0.57 (Book Value of Equity 598.7m / Total Liabilities 1.04b) |
| Altman-Z'' Score: 3.35 = A |
Beneish M -3.03
| DSRI: 0.94 (Receivables 414.9m/391.5m, Revenue 1.63b/1.44b) |
| GMI: 1.00 (GM 31.58% / 31.51%) |
| AQI: 1.04 (AQ_t 0.66 / AQ_t-1 0.64) |
| SGI: 1.13 (Revenue 1.63b / 1.44b) |
| TATA: -0.06 (NI 108.4m - CFO 206.6m) / TA 1.54b) |
| Beneish M-Score: -3.03 = AA |
ValueRay F-Score (Strict, 0-100) 76.16
| 1. Piotroski: 9.0pt |
| 2. FCF Yield: 4.99% |
| 3. FCF Margin: 11.77% |
| 4. Debt/Equity: 1.30 |
| 5. Debt/Ebitda: 2.98 |
| 6. ROIC - WACC: 4.98% |
| 7. RoE: 21.35% |
| 8. Revenue Trend: 96.91% |
| 9. EPS Trend: 29.88% |
What is the price of HURN shares?
Over the past week, the price has changed by -6.61%, over one month by -3.85%, over three months by +11.88% and over the past year by +36.06%.
Is HURN a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HURN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 215.5 | 25.8% |
| Analysts Target Price | 215.5 | 25.8% |
| ValueRay Target Price | 227.3 | 32.7% |
HURN Fundamental Data Overview January 17, 2026
P/E Forward = 21.5517
P/S = 1.9839
P/B = 6.3401
P/EG = 1.5199
Revenue TTM = 1.63b USD
EBIT TTM = 182.9m USD
EBITDA TTM = 210.1m USD
Long Term Debt = 589.6m USD (from longTermDebt, last quarter)
Short Term Debt = 34.1m USD (from shortTermDebt, last quarter)
Debt = 650.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 627.0m USD (from netDebt column, last quarter)
Enterprise Value = 3.84b USD (3.21b + Debt 650.9m - CCE 23.9m)
Interest Coverage Ratio = 5.83 (Ebit TTM 182.9m / Interest Expense TTM 31.4m)
EV/FCF = 20.04x (Enterprise Value 3.84b / FCF TTM 191.5m)
FCF Yield = 4.99% (FCF TTM 191.5m / Enterprise Value 3.84b)
FCF Margin = 11.77% (FCF TTM 191.5m / Revenue TTM 1.63b)
Net Margin = 6.66% (Net Income TTM 108.4m / Revenue TTM 1.63b)
Gross Margin = 31.58% ((Revenue TTM 1.63b - Cost of Revenue TTM 1.11b) / Revenue TTM)
Gross Margin QoQ = 30.55% (prev 33.16%)
Tobins Q-Ratio = 2.49 (Enterprise Value 3.84b / Total Assets 1.54b)
Interest Expense / Debt = 1.69% (Interest Expense 11.0m / Debt 650.9m)
Taxrate = 28.67% (12.2m / 42.6m)
NOPAT = 130.4m (EBIT 182.9m * (1 - 28.67%))
Current Ratio = 1.44 (Total Current Assets 475.0m / Total Current Liabilities 330.1m)
Debt / Equity = 1.30 (Debt 650.9m / totalStockholderEquity, last quarter 499.8m)
Debt / EBITDA = 2.98 (Net Debt 627.0m / EBITDA 210.1m)
Debt / FCF = 3.27 (Net Debt 627.0m / FCF TTM 191.5m)
Total Stockholder Equity = 507.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.54% (Net Income 108.4m / Total Assets 1.54b)
RoE = 21.35% (Net Income TTM 108.4m / Total Stockholder Equity 507.6m)
RoCE = 16.67% (EBIT 182.9m / Capital Employed (Equity 507.6m + L.T.Debt 589.6m))
RoIC = 12.34% (NOPAT 130.4m / Invested Capital 1.06b)
WACC = 7.36% (E(3.21b)/V(3.86b) * Re(8.61%) + D(650.9m)/V(3.86b) * Rd(1.69%) * (1-Tc(0.29)))
Discount Rate = 8.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.20%
[DCF Debug] Terminal Value 83.36% ; FCFF base≈157.4m ; Y1≈194.2m ; Y5≈330.7m
Fair Price DCF = 335.6 (EV 6.41b - Net Debt 627.0m = Equity 5.79b / Shares 17.2m; r=7.36% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 29.88 | EPS CAGR: -33.70% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.91 | Revenue CAGR: 16.57% | SUE: 1.95 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.82 | Chg30d=+0.005 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=8.74 | Chg30d=+0.008 | Revisions Net=+1 | Growth EPS=+14.7% | Growth Revenue=+9.5%
Additional Sources for HURN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle